Clinical trials: Antipsychotic
Schizophrenia, Renal Impairment
A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function
The purpose of this study is to evaluate the pharmacokinetics of a single oral dose of 3 mg extended release paliperidone (ER OROSÃ' paliperidone) in patients with varying degrees of renal impairment (mild, moderate, and severe)…
- Trial name
- NCT00791401
- Testing
- ER OROS Paliperidone
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Metabolic Syndrome, Diabetes
Pharmacogenetic Profiling of Antipsychotics-Induced X-Syndrome and Diabetes (PAXD)
Diabetes is prevalent in schizophrenics and may be induced by antipsychotic treatments. Several retrospective studies have suggested that psychiatric patients exposed to atypical antipsychotics may be at a higher risk for…
- Trial name
- NCT00201292
- Where
- 3 sites in Taiwan
- Volunteers
- 1,350 people
- Sponsor
- National Health Research Institutes, Taiwan
Schizophrenia
Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
The primary objective of the double-blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (3, 9, and 15 mg/day) compared with placebo in adult patients with schizophrenia
- Trial name
- NCT00083668
- Testing
- Paliperidone ER
- Volunteers
- 619 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Conduct Disorder, fMRI
Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders
Background: Some children and teenagers have conditions known as conduct disorders. They often have long-term chronic behavior problems, such as defiant behavior or violence.
- Trial name
- NCT01867398
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Antipsychotic Agents, Bipolar Disorder
Pharmacoepigenetics of Bipolar Disorder Treatment
Insulin is a hormone produced by the body to regulate blood sugar. Insulin resistance is a state when the body is not using insulin correctly, and more insulin is needed to maintain normal blood sugar.
- Trial name
- NCT02374996
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wayne State University
Schizophrenia
Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis
A controlled, randomized study on the treatment of schizophrenic psychosis with cannabidiol, a phytocannabinoid is performed. This approach is based upon recent findings indicating that the human endogenous cannabinoid system is…
- Trial name
- CBD-CT1 (NCT00628290)
- Testing
- Cannabidiol, Amisulpride
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- University of Cologne
Dementia
Effect of Person-Centred-Care on Antipsychotic Drug Use in Nursing Homes: a Cluster-randomised Trial
Background: Up to 90% of nursing home residents with dementia experience behavioural and psychological symptoms like apathy, agitation, and anxiety.
- Trial name
- EPCentCare (NCT02295462)
- Testing
- Person-centered Care, Optimised Treatment
- Where
- 3 sites in Germany
- Volunteers
- 1,158 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Tardive Dyskinesia, Intellectual Disability
Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
The primary goal of this study is to investigate the efficacy of deutetrabenazine treatment of TD in this previously untreated patient population.
- Conditions
- Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
- Trial name
- TD-AIDD (NCT06997198)
- Testing
- Deutetrabenazine Oral Capsule
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia
Determining Metabolic Effects of Valproate and Antipsychotic Therapy
This study will determine the metabolic processes responsible for high levels of blood glucose, metabolism disorders, and weight gain in people with schizophrenia who have been treated with antipsychotic medications in…
- Trial name
- NCT00167934
- Testing
- Valproate
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- Washington University School of Medicine
Antipsychotic-induced Weight Gain (AIWG)
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
This Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic…
- Trial name
- NCT04524403
- Testing
- Miricorlilant
- Where
- 40 sites in United States
- Volunteers
- 150 people
- Sponsor
- Corcept Therapeutics
Drug-induced Extrapyramidal Side Effects
Extrapyramidal Side-Effects in Antipsychotic Drug Therapeutics
The project is aimed at addressing the fundamental issue in antipsychotic therapeutics -the balance between mental state benefits and neurological risks.The latter cannot be overestimated and clinical skills in themselves are…
- Trial name
- NCT02366897
- Testing
- Manus Sensor Pen
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- University of Edinburgh
Schizophrenia
A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)
This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia.
- Trial name
- NCT01235520
- Testing
- RO4917838
- Where
- 121 sites in United States, Argentina and 12 more
- Volunteers
- 595 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients
Standard antipsychotic drug regimens do not fully address the impact of cognitive symptoms associated with schizophrenia. The NMDA receptor has been connected to the pathophysiology of schizophrenia.
- Trial name
- NCT00097942
- Testing
- memantine HCl
- Where
- 13 sites in United States
- Volunteers
- 138 people
- Sponsor
- Forest Laboratories
Antipsychotics, Pregnancy
Maternal And Infant Antipsychotic Study
The goal of this observational study is to learn about maternal psychiatric course and infant development in pregnant individuals with severe mental illness, comparing those treated with antipsychotics to those treated with other…
- Trial name
- MAIA (NCT06049953)
- Testing
- Antipsychotics, Non-antipsychotic medication, No Medication
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Schizophrenia, Metabolic Syndrome X
An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics
The purpose of the study is to find and follow-up the metabolic syndrome parameters on patients administering atypical antipsychotics.
- Trial name
- MESSAGE (NCT00448630)
- Testing
- No intervention
- Where
- 47 sites in Turkey (Türkiye)
- Volunteers
- 328 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizoaffective Disorder
PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders
The purpose of this study is to evaluate epidemiological characteristics of patients that experience relapse and need an admission in psychiatric acute units across Spain.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00399334
- Testing
- antipsychotic medications
- Volunteers
- 1,607 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia
Effects of Exposed to Antipsychotics Throughout Pregnancy on Infants Development: A Prospective Study
The primary aim of this prospective study is to evaluate the effect of antipsychotics on infant development especially neurobehavioral development which evaluated by the Bayley-III when mothers are treated with antipsychotics…
- Trial name
- NCT01479400
- Where
- China
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Central South University
Schizophrenia
Bexarotene Treatment in Schizophrenia
In this proposed study, we aim to investigate the effects of Bexarotene (Targretin; LGD1069; 4-[1-{5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl} ethenyl] benzoic acid) on severity of psychopathology, cognitive…
- Trial name
- NCT00141947
- Testing
- bexarotene (Targretin)
- Where
- 2 sites in Israel
- Volunteers
- 15 people
- Sponsor
- Beersheva Mental Health Center
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bipolar Disorder
Comparative Effectiveness Study for Bipolar Disorder
The purpose of this study is to compare the effectiveness of lithium and quetiapine for the treatment of individuals with bipolar disorder.
- Trial name
- NCT01331304
- Testing
- Lithium, Quetiapine
- Where
- 11 sites in United States
- Volunteers
- 482 people
- Sponsor
- Massachusetts General Hospital